netFormulary George Eliot Hospital NHS
NHS Trust  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
The development of this chapter for the George Eliot Formulary is in progress
 Details...
08.01.06  Expand sub section  Other antineoplastic drugs
Cytotoxic Drug AfliberceptBlack Triangle (Zaltrap®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Link  NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Link  NICE TA346: Aflibercept for treating diabetic macular oedema
Link  NICE TA486: Aflibercept for treating choroidal neovascularisation
   
Cytotoxic Drug AtezolizumabBlack Triangle (Tecentriq®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
Cancer Drugs Fund
 
Link  NICE TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
   
Cytotoxic Drug DaratumumabBlack Triangle (Darzalex®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
Cancer Drugs Fund
 
Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
   
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO

BlueTeq for NICE TA423

 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Link  NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
   
Cytotoxic Drug PanobinostatBlack Triangle (Farydak®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq
 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Cytotoxic Drug Pertuzumab (Perjeta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Link  Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Procarbazine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
   
Cytotoxic Drug Raltitrexed (Tomudex®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
   
Cytotoxic Drug TivozanibBlack Triangle (Fotivda®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
Cancer Drugs Fund
 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
   
VenetoclaxBlack Triangle (Venclyxto)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
Cancer Drugs Fund
 
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
   
08.01.06  Expand sub section  Bevacizumab
Bevacizumab (Avastin®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary

CDF for first line treatment of recurrent or metastatic cervical cancer in combination with chemotherapy, third line treatment of glioma in childhood and first line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

 
Link  NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Link  NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Link  NICE TA214: Breast Cancer with taxane
Link  NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Link  NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
   
08.01.06  Expand sub section  Bortezomib
Bortezomib (Velcade®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary

CDF for the treatment of bortezomib naive relapsed multiple myeloma

 
Link  NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Link  NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Link  NICE TA299: Leukaemia (chronic myeloid) - bosutinib
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
   
08.01.06  Expand sub section  Brentuximab vedotin
Brentuximab vedotin (Adcetris®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary

CDF for relapsed or refractory CD30+ Hodgkin's lymphona after at least 2 previous therapies and cannot have autologous stem cell translplant or multi-agent chemotherapy

BlueTeq for relapsed or refractory CD30+ Hodgkin's lymphona after autologous stem cell transplant and for relapsed or refractory systemic large cell lymphoma

 
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
   
08.01.06  Expand sub section  Cetuximab to top
Cetuximab (Erbitux®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
BlueTeq
 
Link  NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Link  NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Link  NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
Link  NICE TA176: Colorectal cancer (first line) - cetuximab
Link  NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
   
08.01.06  Expand sub section  Hydroxycarbamide
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
08.01.06  Expand sub section  Panitumumab
Panitumumab (Vectibix®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
Link  NICE TA242: NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
08.01.06  Expand sub section  Pentostatin
Cytotoxic Drug Pentostatin (Nipent®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
08.01.06  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Cytotoxic Drug Cisplatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Link  NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
   
08.01.06  Expand sub section  Porfimer sodium and temoporfin to top
08.01.06  Expand sub section  Protein kinase inhibitors
Cytotoxic Drug AxitinibBlack Triangle (Inlyta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
   
Cytotoxic Drug BosutinibBlack Triangle (Bosulif®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq
 
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
   
Cytotoxic Drug CabozantinibBlack Triangle (Cometriq® Cabometyx®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq
 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Cytotoxic Drug CrizotinibBlack Triangle (Xalkori®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO

CDF for NICE TA529 if the conditions in the managed access agreement are followed.

BlueTeq for NICE TA406 and NICE TA422

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
   
Cytotoxic Drug Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO

BlueTeq for NICE TA426

 
Link  NICE TA241: CML for whom treatment with imatinib has failed because of intolerance
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Cytotoxic Drug Everolimus (Afinitor®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq

BlueTeq for NICE TA421, TA432 and TA449

 
Link  NICE TA219: Everolimus for second-line treatment of renal cell cancer
Link  NICE TA295: Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor):
Link  NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Cytotoxic Drug Gefitinib (Iressa®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Cytotoxic Drug IbrutinibBlack Triangle (Imbruvica®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq
 
Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Cytotoxic Drug Imatinib (Gilvec®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA196: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
   
Cytotoxic Drug LenvatinibBlack Triangle (Kisplyx®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq
  • For use with everolimus
 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Cytotoxic Drug Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq
 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Cytotoxic Drug OsimertinibBlack Triangle (Tagrisso®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
Cancer Drugs Fund
 
Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
   
Cytotoxic Drug PalbociclibBlack Triangle (Ibrance®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq
 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Cytotoxic Drug Pazopanib (Votrient®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
   
Cytotoxic Drug RuxolitinibBlack Triangle (Jakavi®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq
 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Cytotoxic Drug Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
Cancer Drugs Fund
BlueTeq
 
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Cytotoxic Drug Sunitinib (Sutent®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq
 
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
   
Cytotoxic Drug Temsirolimus (Torisel®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
   
Cytotoxic Drug Vemurafenib (Zelboraf®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
   
08.01.06  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel (Jevtana®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq
 
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Cytotoxic Drug Docetaxel
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Link  NICE TA109: Breast cancer (early) - docetaxel
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA108: Breast cancer (early) - paclitaxel
Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
   
Cytotoxic Drug Paclitaxel albumin (Abraxane®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
BlueTeq
 
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
   
08.01.06  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan Hydrochloride
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
   
Cytotoxic Drug Topotecan
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
 
Link  NICE TA183: Topotecan for the treatment of relapsed small-cell lung cancer
Link  NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
   
08.01.06  Expand sub section  Trabectedin
08.01.06  Expand sub section  Trastuzumab to top
Cytotoxic Drug Trastuzumab (Herzuma®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
  • When prescribing, dispensing or administering, check that this is the correct preparation - trastuzumab emtansine and trastuzumab are NOT interchangeable. 
 
Link  NICE TA107: Breast cancer (early) - trastuzumab
Link  NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
Link  NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Trastuzumab emtansineBlack Triangle (Kadcyla®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
  • When prescribing, dispensing or administering, check that this is the correct preparation - trastuzumab emtansine and trastuzumab are NOT interchangeable. 
 
Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Link  Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Link  Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
   
08.01.06  Expand sub section  Tretinoin
08.01.06  Expand sub section  Vismodegib
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red SO

SPECIALIST ONLY - These drugs are deemed to be not appropriate for prescribing by GPs. Specialists should not ask GPs to prescribe these drugs.   

Green SI

SPECIALIST INITIATED - These drugs must be initiated, i.e. the first dose prescribed, by the specialist and then may be continued when appropriate by the patients GP following communication from the specialist.   

Green SA

SPECIALIST ADVISED – Specialists may simply advise a patients GP to initiate these drugs themselves after they have made an initial assessment.   

Amber SC

SHARED CARE - Responsibility for prescribing may be transferred from secondary to primary care with the agreement of an individual GP and when agreed shared care arrangements have been established. The specialist MUST stabilize the patient before asking for care to be transferred. Only specialists should initiate these drugs. Prescribing should be transferred to GPs according to an Shared Care Agreement [SCA]   

netFormulary